drugset / Trial / NCT04940871
Study to Assess the Efficacy and Safety of Favipiravir-HU
Phase 2
Terminated
1 enrolled
University of Pecs
Hungarian Ministry of Innovation and Technology · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of the study is to assess the safety and efficacy of Favipiravir HU when administered to SARS-Cov- 2 patients in order to offer a safe and effective treatment to SARS-Cov-2 infection during the pandemic. The study is not for registration purposes and is not part of a series of studies for registration of Favipiravir HU.
Timeline
- Start
- 2021-11-25
- Primary completion
- 2021-11-29
- Completion
- 2021-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 200 mg | Oral |